Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences
Mené sur 1 052 patients atteints d'un cancer métastatique de la prostate résistant à la castration, cet essai de phase III évalue, du point de vue de la survie globale, l'ajout de zibotentan, un antagoniste du récepteur de l'endothéline de type A, au docétaxel
Ever since docetaxel was shown to be the first known agent to extend survival in men with metastatic castration-resistant prostate cancer (mCRPC), drug development efforts have focused on docetaxel as a pivot point for trial design and regulatory approval. To this end, the majority of phase III clinical trials conducted in the postdocetaxel era have investigated the use of novel agents either before docetaxel administration, combined with docetaxel, or after docetaxel exposure...
Journal of Clinical Oncology , éditorial en libre accès, 2013